经观评论 日前，国家医保局发布第十一批国家组织药品集中采购文件。此次药品集采涉及55种药品，包括抗感染、抗肿瘤、抗过敏、糖尿病用药、心血管用药等。尽 管这是一次常态化的集采，但市场对其关注度超过以往。各方最大的关切或许是，新的竞标规则将对集采结果产生怎样的影响？ 今年6月13日举行的国务院常务会议指出，要加强药品和耗材集采政策评估，总结经验、补齐短板，推动集采工作规范化制度化常态化开展。此后，国家医 保局按照"稳临床、保质量、防围标、反内卷"的原则，研究优化了具体的采购规则。现实地看，这是对此前市场和医患关切的积极回应，也是采购规则的进 如果说，价格一端的调整有"减压"的意思，在质量一端则体现了持续的高压态势——这也是医生和患者最关切的问题。新规则要求，投标药品的生产线两年 内不存在违反药品生产质量管理规范的情形，药监部门对集采中选企业检查和产品抽检两个"全覆盖"。 我们注意到，新规则增加了针对市场主流品牌的"复活"机制，允许在第一轮落选的市场主流品牌，以该轮最高拟中选价格获得中选资格。"复活"机制体现了 对优质品牌市场价值的认可，也为其提供了一定的保护空间——这是一张企业过往研发投入与市场声誉织就的 "安全 ...

新规则的指向非常明确，就是避免制药企业陷入内卷式恶性竞 争。在保证质量的前提下，患者希望得到更友好的价格，这也 符合医保控费的要求。一味追求低价甚至低于成本竞价，很可 能适得其反，既不利于患者也不利于行业的健康发展。 作者： 社论 封图：图虫创意 日前，国家医保局发布第十一批国家组织药品集中采购文件。此次药品集采涉及55种药品，包括 抗感染、抗肿瘤、抗过敏、糖尿病用药、心血管用药等。尽管这是一次常态化的集采，但市场对其 关注度超过以往。各方最大的关切或许是，新的竞标规则将对集采结果产生怎样的影响？ 今年6月13日举行的国务院常务会议指出，要加强药品和耗材集采政策评估，总结经验、补齐短 板，推动集采工作规范化制度化常态化开展。此后，国家医保局按照"稳临床、保质量、防围标、 反内卷"的原则，研究优化了具体的采购规则。现实地看，这是对此前市场和医患关切的积极回 应，也是采购规则的进一步完善。 我们注意到，新规则增加了针对市场主流品牌的"复活"机制，允许在第一轮落选的市场主流品牌， 以该轮最高拟中选价格获得中选资格。"复活"机制体现了对优质品牌市场价值的认可，也为其提供 了一定的保护空间——这是一张企业过往研发投入与 ...

Group 1: Industry Overview - Approximately 70% of allergy medications in China are produced in Hainan, with a significant contribution from Wante Pharmaceutical (Hainan) Co., Ltd, a private enterprise with over 20 years in the region [1] - Hainan Baolu Aquatic Technology Co., Ltd has developed the 21st generation of tilapia fry, achieving a growth rate improvement of 300% compared to the first generation, exporting 1 billion fry annually to global markets [1] - As of June 2023, Hainan has 3.6044 million private business entities, accounting for 97.54% of the province's total, contributing 60% of GDP, 80% of tax revenue, and nearly 90% of employment [1] Group 2: Innovation and R&D - Jindan Technology Co., Ltd has transformed from a single transformer product company to a smart manufacturing leader with nearly 7 billion yuan in annual revenue, investing 356 million yuan in R&D in 2024 [2] - Hainan Huayan Collagen Technology Co., Ltd focuses on high-value utilization of marine resources, converting fish by-products into small molecule peptides for various applications, supported by a highly educated R&D team [2] - In 2024, the top 20 private enterprises in Hainan are expected to invest a total of 3.763 billion yuan in R&D, holding 1,199 valid patents and participating in the formulation of 335 standards [2] Group 3: Policy Support - Jingrun Pearl, the first company in Hainan's pearl processing industry to benefit from a 30% processing value-added tax exemption, has imported 16,300 pearls this year, saving over 1 million yuan in taxes [3] - The 10.56 billion yuan lithium hydroxide project in Yangpu is expected to generate over 2 billion yuan in annual output value, benefiting from Hainan's zero-tariff policy [3] - Hainan has implemented a series of policies, including a 15% income tax reduction for businesses and individuals, to enhance the business environment and support private enterprises [4] Group 4: Business Environment - Hainan's first batch of soybean oil from AOSK International Grain and Oil was exported to India, showcasing the province's efficient business environment that allows rapid project completion [5] - The Hainan government has introduced measures to optimize the business environment, including a one-stop service platform for policies and direct communication channels between government and enterprises [5] - The Hainan Free Trade Port is set to enhance the global competitiveness of private enterprises, with companies like Hainan Shengsen Pharmaceutical Co., Ltd planning to establish R&D centers and expand international markets [6]